Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine

Journal of the National Cancer Institute

Volumn 87, Issue 13, 1995, Pages 982-990

  Tsang, Kwong Y ^a   Zaremba, Sam ^a   Nieroda, Carol A ^a   Zhu, Ming Z ^a   Hamilton, J Michael ^a   Schlom, Jeffrey ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; HLA A1 ANTIGEN; HLA A2 ANTIGEN; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN; PEPTIDE; TUMOR NECROSIS FACTOR ALPHA; VACCINE; VIRUS VECTOR;

AMINO ACID SEQUENCE; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; FLOW CYTOMETRY; GENE; HUMAN; HUMAN CELL; IMMUNIZATION; VACCINIA VIRUS;

AMINO ACID SEQUENCE; CARCINOEMBRYONIC ANTIGEN; CARCINOMA; COLORECTAL NEOPLASMS; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMAN; IMMUNODOMINANT EPITOPES; MOLECULAR SEQUENCE DATA; T-LYMPHOCYTES; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL VACCINES;

EID: 0029042336     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/87.13.982     Document Type: Article

References (48)

1. van der Bruggen P, Traversari C, Chômez P, et al: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643-1647,1991
2. Horn SS, Topalian SL, Simonis T, et al: Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction. J Immurtother10:153-164,1991
3. Cox AL, Skipper J, Chen Y, et al: Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:7l5-719, 1994
4. Darrow TL, Slingluff CL Jr, Seigler HF: The role of HLA Class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens. J Immunol 142:3329-3335, 1989
5. Oesterling JE: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145:907-923,1991
6. Peace DJ, Xue BH, Sosman JA, et al: In vitro immunization of human cytotoxic T lymphocytes specific for peptides derived from prostate specific antigen. Cancer Vaccine Symposium. Cancer Research Institute. Oct. 3-5, 1994.
7. Fisk B, Chesak B, Ioannides MG, et al: Sequence motifs of human HER-2 proto-oncogene important for peptide binding to HLA-A2. Int J Oncol5:51-63,1994
8. Ioannides CG, Fish B, Jerome KR, et al: Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol 151:3693-3703, 1993
9. Tsang KY, Nieroda CA, De Filippi R, et al: Induction of human cytotoxic T-cell lines directed against point-mutated p21 ras-derived synthetic peptides. Vaccine Res 3:183-193,1994
10. Jung S, Schluesener HJ: Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins. J Exp Med 173:273-276,1991.
11. Fenton RG, Taub DD, Kwak LW, et al: Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes [see comment citation in Medline], J Natl Cancer Inst 85:1294-1302,1993
12. Houbiers JG, Nijman HW, van der Burg SH, et al: In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol 23:2072-2077, 1993
13. Kantor J, Irvine K, Abrams S, et al: Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine [see comment citation in Medline]. J Natl Cancer Inst84:1084-1091,1992
14. Kantor J, Irvine K, Abrams S, et al: Immunogenicity and safety of a recombinant vaccinia virus vaccine'expressing the carcinoembryonic antigen gene in a nonhuman primate. Cancer Res 52:6917-6925, 1992.
15. Ras E, VanderBerg SH, Wamaar SO: Identification of potential tumor-specific CTL epitopes of epithelial surface antigen (ESA) and carcinoembryonic antigen (CEA). European Immunology Meeting, Barcelona, June 1994.
16. Thompson JA, Grunert F, Zimmermann W: Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal5:344-366,1991
17. Oikawa S, Imajo S, Noguchi T, et al: The carcinoembryonic antigen (CEA) contains multiple immunoglobulin-like domains. Biochem Biophys Res Commun 144:634-642, 1987
18. Staab HJ, Anderer FA, Stumpf E, et al: Are circulating CEA immune complexes a prognostic marker in patients with carcinoma of the gastrointestinal tract? BrJ Cancer 42:26-33, 1980.
19. Mavligit GM, Stuckey S: Colorectal carcinoma. Evidence for circulating CEA-anti-CEA complexes. Cancer 52:146-149, 1983.
20. Collatz E, Von Kleist S, Burtin P: Further investigations of circulating antibodies in colon cancer patients: on the autoantigenicity of the carcinoembryonic antigen. Int J Cancer 8:298-303, 1971.
21. Chester KA, Begent RH: Circulating immune complexes (CIQ), carcinoembryonic antigen (CEA) and CIC containing CEA as markers for colorectal cancer. Clin Exp Immunol 58:685-693, 1984.
22. Ura Y, Ochi Y, Hamazu M, et al: Studies on circulating antibody against carcinoembryonic antigen (CEA) and CEA-like antigen in cancer patients. Cancer Lett 24:283-295, 1985
23. Hamilton JM, Chen AP, Nguyen B, et al: Phase I study of recombinant vacinnia virus (rV) that expresses human carcinoembryonic antigen (CEA) in adult patients with adenocarcinomas. Proc ASCO:abstr 961, 1994.
24. Gritz L, Destree A, Cormier N, et al: Generation of hybrid genes and proteins by vaccinia virus-mediated recombination: application to human immunodeficiency virus type 1 env. J Virol 64:5948-5957, 1990.
25. Anderson KS, Alexander J, Wei M, et al: Intracellular transport of class I MHC molecules in antigen processing mutant cell lines. J Immunol151:3407-3419,1993
26. Blumberg RS, Panadis T, Byington R, et al: Effects of human immunodeficiency virus on the cellular immune response to Epstein-Barr virus in homosexual men: characterization of the cytotoxic response and lymphokine production. J Infect Dis 155:877-890, 1987.
27. Robbins PF, Kantor JA, Salgaller M, et al: Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. Cancer Res 51:3657-3662,1991
28. Tsang KY, Kashmiri SV, De Filippi R, et al: A human T cell line engineered to secrete chimeric monoclonal antibody. J Immunother 13:143-152,1993
29. Boyum A: A one-stage procedure for isolation of granulocytes and lymphocytes from human blood. General sedimentation properties of white blood cells in a lg gravity field. Scand J Clin Lab Invest 97(suppl):51-76, 1968
30. Guadagni F, Witt PL, Robbins PF, et al: Regulation of carcinoembryonic antigen expression in different human colorectal tumor cells by interferon-y. Cancer Res 50:6248-6255,1990
31. Nijman HW, Houbiers JG, Vierboom MP, et al: Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur J Immunol 23:1215-1219, 1993
32. O’Neil BH, Kawakami Y, Restifo NP, et al: Detection of shared MHC-restricted human melanoma antigens after vaccinia virus-mediated transduction of genes coding for HLA. J Immunol 151:1410-1418, 1993.
33. Falk K, Rotzschke O, Stevanovic S, et al: Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature351:290-296,1991
34. Hunt DF, Henderson RA, Shabanowitz J, et al: Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 255:1261-1263,1992
35. Lee J: The HLA System: A New Approach. New York: Springer-Verlag, 1990, p 154
36. Parker KC, Bednarek MA, Coligan JE: Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152:163-175,1994
37. DiBrino M, Parker KC, Shiloach J, et al: Endogenous peptides bound to HLA-A3 possess a specific combination of anchor residues that permit identification of potential antigenic peptides. Proc Natl Acad Sci U S A90:1508-1512,1993
38. Fuchs C, Krapf F, Kern P, et al: CEA-containing immune complexes in sera of patients with colorectal and breast cancer-analysis of complexed immunoglobulin classes. Cancer Immunol Immunother 26:180-184, 1988.
39. Abeyounis CL, Wilhelm SA, Rittenhouse KW, et al: Is carcinoembryonic antigen an autoantigen? Transplant Proc 16:489-491, 1984.
40. MacSween JM: The antigenicity of carcinoembryonic antigen in man. Int J Cancer 15:246-252,1975
41. Steele G Jr, Lahey S, Rodrick M, et al: Circulating immune complexes in patients with colorectal cancer. Am J Surg 145:549-553, 1983.
42. Conry RM, Saleh MN, Schlom J, et al: Breaking tolerance to carcinoembryonic antigen with a recombinant vaccinia virus vaccine in man. Proc Am Assoc Cancer Res 36:abstr492, 1995
43. Foon KA, Chakrabarty M, John W, et al: Active immunity to the car-cinoembyonic antigen (CEA) in patients treated with an anti-idiotype monoclonal antibody vaccine. Proceedings of the 9th Annual Meeting of the Society for Biological Therapy, Oct 26-20, 1994.
44. Ftshbein GE, McClay E, Berd D, et al: A postsurgical adjuvant trial of CEA immunization in patients with Dukes C and D colorectal cancer a pilot study. Vaccine Res 1:123-128, 1992
45. Rosenberg SA, Yannelli JR, Yang JC, et al: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 86:1159-1166, 1994
46. Gavioli R, Kurilla MG, DeCampos-Lima PO, et al: Multiple HLA-A11-restricted cytotoxic T-lymphocyte epitopes of different imunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4. J Virol 67:1572-1578, 1993
47. Oldstone MB, Tishon A, Geckeler R, et al: A common antiviral cytotoxic T-lymphocyte epitope for diverse major histocompatibility complex haplotypes: implications for vaccination. Proc Natl Acad Sci U S A 89:2752-2755, 1992
48. Hodge JW, Abrams S, Schlom J, et al: Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res 54:5552-5555,1994